Transforming industry leadership - Bristol Myers Squibb

Transforming industry leadership

We are partnering with Historically Black Colleges and Universities (HBCUs) to nurture promising young professionals among underrepresented groups.

Despite representing roughly 12 percent of the US adult population, in biopharma, Black/African American professionals account for just 7 percent of the total US workforce and 3 percent of US executive teams. 

In August 2021, Bristol Myers Squibb entered into a strategic collaboration with Florida A&M University, Howard University, Morgan State University, North Carolina A&T University and University of Arkansas at Pine Bluff to build a sustainable bridge for diverse talent to the biopharma industry.

The Tomorrow’s Innovators program will develop a two-way leadership exchange program for collaboration and research purposes, increase talent recruitment from HBCUs and attract executive-level Black/African American talent. We also seek to enhance the student educational experience at participating HBCUs through custom programming and experiences designed to introduce biopharma to Black/African American students earlier in their educational journey.

This collaboration extends the health equity and diversity and inclusion commitments announced in 2020, which include the goal of increasing the diversity of the company’s workforce. Together, we will build the incubator for the industry’s future leaders to create a more diverse and equitable future in healthcare.

More Community Stories


The power of inclusion >
Expanding clinical trial diversity >
Environmental, social & governance highlights >
Pursuing sustainable science >
Transforming patients' lives through science

The touch that transforms

2021 Annual Report


Visit to see how we're bringing a human touch to everything we do. 

The patient stories shared in this Annual Report depict individual patient responses to our medicines or investigational compounds and are not representative of all patient responses. In addition, there is no guarantee that potential drugs or indications still in development will receive regulatory approval. This Annual Report contains statements about the company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ from those indicated as a result of various important factors, including those discussed in the company’s most recent annual report on Form 10-K and reports on Form 10-Q and Form 8-K. These documents are available from the SEC, the Bristol-Myers Squibb website or from Bristol-Myers Squibb Investor Relations. In addition, any forward-looking statements represent our estimates only as of the date hereof and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change. This Annual Report also contains certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures are available on the company’s website at